Beyond the biotech IPO: a brave new world

Abstract

After a decade of significant challenges, biotech's long-term sustainability depends on making fundamental changes to its traditional business model. The biotech sector needs to focus three central strategies: first, create companies with leaner, more focused business models; second, fund more innovative and less incremental therapies; and third, capture value over the long term by engaging larger firms as collaborative risk-sharing partners earlier in the corporate life cycle.